Repare Therapeutics Inc 's Cash & cash equivalent grew by 2.86 % in the Q3 2025 sequentially, while Current Liabilities decreased, this led to improvement in Repare Therapeutics Inc 's Quick Ratio to 30.54, above Repare Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Quick Ratio than Repare Therapeutics Inc in third quarter 2025. While Quick Ratio total ranking has improved so far during the Q3 2025 to 117, from total ranking in the second quarter 2025 at 458.

Explain Quick Ratio?
How much Cash & cash equivalents RPTX�s has?
What are RPTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RPTX Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	-88.14 %	-36.13 %	-42.58 %	-35.29 %	-36.53 %
Y / Y Cash & cash equivalent Change	-37.24 %	-47.4 %	-47.58 %	-31.68 %	-28.25 %
Quick Ratio MRQ	30.54	5.45	7.08	6.04	5.77
RPTX's Total Ranking	# 117	# 458	# 342	# 208	# 504
Seq. Current Liabilities Change	-81.64 %	14.42 %	-30.58 %	-18.65 %	-1.16 %
Seq. Cash & cash equivalent Change	2.86 %	-11.88 %	-18.69 %	-14.85 %	-13.79 %

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 15
Healthcare Sector	# 26
Overall Market	# 117

Quick Ratio Statistics
High	Average	Low
37.76	13.38	3.88
(Jun 30 2020)		(Mar 31 2023)

Financial Statements
Repare Therapeutics Inc 's Current Liabilities	$ 4 Millions	Visit RPTX's Balance sheet
Repare Therapeutics Inc 's Cash & cash equivalent	$ 113 Millions	Visit RPTX's Balance sheet
Source of RPTX's Sales		Visit RPTX's Sales by Geography

Cumulative Repare Therapeutics Inc 's Quick Ratio

RPTX's Quick Ratio for the trailling 12 Months

RPTX Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-49.61 %	-37.36 %	-38.69 %	-46.73 %	-49.51 %
Y / Y Cash & cash equivalent TTM Growth	-41.16 %	-38.41 %	-32.97 %	-27.25 %	-28.65 %
Quick Ratio TTM	7.49	6.02	6.31	6.57	6.42
Total Ranking TTM	# 3473	# 2915	# 2936	# 2195	# 1836
Seq. Current Liabilities TTM Growth	-29.14 %	-10.78 %	-10.99 %	-10.43 %	-11.92 %
Seq. Cash & cash equivalent TTM Growth	-11.81 %	-14.84 %	-14.51 %	-8.35 %	-7.69 %

Quick ratio ranking by company, industry and sector >> Back to RPTX Financial Strength Comparisons >> Go to Compare RPTX Quick Ratio to its Competitors

News about Repare Therapeutics Inc Quick Ratio

Investigating Innovations in Precision Oncology Repare Therapeutics to Showcase Groundbreaking Research at the AACR A...

: Repare Therapeutics Inc. a notable player in the field of precision oncology, has announced the acceptance of six abstracts for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting scheduled for April 25-30, 2025, in Chicago, Illinois. This achievement not only underscores the company’s commitment to advancing cancer treatment but also highlights the promising innovations emerging from its research pipeline. Corporate Overview: Repare Therapeutics Inc. (NASDAQ: RPTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics designed to exploit the unique vulnerabilities of cancer cells. The company s innovative approach revolves around leveraging synthetic lethality a concept that targets the underlying genetic makeup of tumors while sparing normal cells. This method holds the potential for creating therapies that are both highly effective and exhibit less toxicity compared to traditional cancer treatments. Research Presentations at AACR 2025: Among the six abstracts accepted for presentation at the AACR Annual Meeting, two will be delivered as minioral presentations while the remaining four will be featured as poster presentations. The encapsulated research covers important clinical and preclinical findings concerning Repare’s investigational drugs and therapeutic approaches, emphasizing the company s ongoing efforts to improve patient outcomes in oncology. The first minioral presentation will detail the efficacy and safety of a combination therapy developed by Repare, showcasing data that could redefine treatment paradigms for specific cancer types. The results will be critical for understanding the potential benefits and risks associated with this novel approach in the provision of personalized cancer care.

On the trailing twelve months basis Current Liabilities decreased faster than Repare Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Repare Therapeutics Inc 's Quick Ratio to 7.49, Quick Ratio remained below RPTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 444 other companies have achieved higher Quick Ratio than Repare Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2915 to 3473.

Explain Quick Ratio?
How much Cash & cash equivalents RPTX�s has?
What are RPTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 445
Healthcare Sector	# 899
Within the Market	# 3473

trailing twelve months Quick Ratio Statistics
High	Average	Low
31.56	10.5	4.54
(Mar 31 2021)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Gh Research Plc	65.06	$ 249.654 Millions	$ 3.837 Millions
Lb Pharmaceuticals Inc	53.15	$ 314.479 Millions	$ 5.917 Millions
Benitec Biopharma Inc	50.23	$ 94.534 Millions	$ 1.882 Millions
Monopar Therapeutics Inc	49.71	$ 127.677 Millions	$ 2.569 Millions
Curanex Pharmaceuticals Inc	46.70	$ 5.831 Millions	$ 0.125 Millions
Altimmune inc	43.88	$ 210.776 Millions	$ 4.804 Millions
Xbiotech Inc	41.34	$ 147.367 Millions	$ 3.565 Millions
Belite Bio Inc	36.61	$ 352.932 Millions	$ 9.641 Millions
Rapport Therapeutics Inc	35.84	$ 513.026 Millions	$ 14.316 Millions
Bright Minds Biosciences Inc	35.59	$ 63.669 Millions	$ 1.789 Millions
Janux Therapeutics Inc	35.54	$ 988.993 Millions	$ 27.831 Millions
Inhibitor Therapeutics Inc	34.01	$ 2.977 Millions	$ 0.088 Millions
Disc Medicine Inc	33.50	$ 615.920 Millions	$ 18.383 Millions
Roivant Sciences Ltd	32.77	$ 4,385.835 Millions	$ 133.857 Millions
Mbx Biosciences Inc	32.47	$ 391.673 Millions	$ 12.062 Millions
Upstream Bio Inc	31.28	$ 372.427 Millions	$ 11.908 Millions
Repare Therapeutics Inc	30.54	$ 112.604 Millions	$ 3.687 Millions
Keros Therapeutics Inc	28.78	$ 693.472 Millions	$ 24.092 Millions
Contineum Therapeutics Inc	28.68	$ 182.407 Millions	$ 6.361 Millions
Viking Therapeutics Inc	27.88	$ 714.570 Millions	$ 25.630 Millions
Liquidia Corporation	26.17	$ 157.496 Millions	$ 6.019 Millions
Edgewise Therapeutics inc	26.03	$ 563.340 Millions	$ 21.646 Millions
Prothena Corporation Public Limited Company	25.09	$ 330.843 Millions	$ 13.188 Millions
Immuneering Corporation	24.83	$ 227.563 Millions	$ 9.164 Millions
Psyence Biomedical ltd	23.53	$ 7.150 Millions	$ 0.304 Millions
Lava Therapeutics Nv	23.48	$ 99.364 Millions	$ 4.231 Millions
Trevi Therapeutics Inc	22.29	$ 194.927 Millions	$ 8.745 Millions
Ligand Pharmaceuticals Incorporated	21.76	$ 664.522 Millions	$ 30.539 Millions
Aprea Therapeutics Inc	21.39	$ 13.718 Millions	$ 0.641 Millions
Stoke Therapeutics Inc	21.34	$ 248.310 Millions	$ 11.634 Millions

Date modified: 2026-09-26T07:38:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.